State Street’s Neurogene NGNE Stock Holding History

State Street’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.31M	Buy	313,005 +5,208	+2%	+$101K	﹤0.01%	2842
2025 Q4	$6.34M	Buy	307,797 +99,487	+48%	+$2.48M	﹤0.01%	2877
2025 Q3	$3.61M	Sell	208,310 -2,538	-1%	-$51K	﹤0.01%	3124
2025 Q2	$3.15M	Sell	210,848 -19,690	-9%	-$309K	﹤0.01%	3139
2025 Q1	$2.7M	Buy	230,538 +5,165	+2%	+$89.7K	﹤0.01%	3135
2024 Q4	$5.15M	Sell	225,373 -21,167	-9%	-$788K	﹤0.01%	2960
2024 Q3	$10.3M	Buy	246,540 +36,687	+17%	+$1.42M	﹤0.01%	2585
2024 Q2	$7.64M	Buy	209,853 +178,626	+572%	+$6.3M	﹤0.01%	2728
2024 Q1	$1.59M	Buy	+31,227	New	+$1.04M	﹤0.01%	3353
2023 Q4	–	Sell	-6,128	Closed	-$96.8K	–	4472
2023 Q3	$96.8K	Hold	6,128	–	–	﹤0.01%	4122
2023 Q2	$102K	Hold	6,128	–	–	﹤0.01%	4235
2023 Q1	$85.8K	Hold	6,128	–	–	﹤0.01%	4367
2022 Q4	$62.4K	Hold	6,128	–	–	﹤0.01%	4504
2022 Q3	$78K	Hold	6,128	–	–	﹤0.01%	4543
2022 Q2	$126K	Sell	6,128 -23,153	-79%	-$565K	﹤0.01%	4412
2022 Q1	$1.1M	Buy	29,281 +282	+1%	+$16.5K	﹤0.01%	3774
2021 Q4	$2.79M	Sell	28,999 -1,522	-5%	-$185K	﹤0.01%	3529
2021 Q3	$4.41M	Sell	30,521 -31,234	-51%	-$4.78M	﹤0.01%	3304
2021 Q2	$11.4M	Sell	61,755 -17,198	-22%	-$3.8M	﹤0.01%	2841
2021 Q1	$19.4M	Buy	78,953 +20,085	+34%	+$5.13M	﹤0.01%	2385
2020 Q4	$16.6M	Buy	58,868 +31,039	+112%	+$7.58M	﹤0.01%	2348
2020 Q3	$6.68M	Buy	27,829 +2,472	+10%	+$599K	﹤0.01%	2651
2020 Q2	$8.42M	Buy	25,357 +24,669	+3,586%	+$6.43M	﹤0.01%	2515
2020 Q1	$157K	Buy	688 +80	+13%	+$16.5K	﹤0.01%	3592
2019 Q4	$150K	Hold	608	–	–	﹤0.01%	3659
2019 Q3	$35K	Hold	608	–	–	﹤0.01%	3740
2019 Q2	$29K	Hold	608	–	–	﹤0.01%	3752
2019 Q1	$33K	Hold	608	–	–	﹤0.01%	3692
2018 Q4	$26K	Sell	608 -1,062	-64%	-$51.7K	﹤0.01%	3707
2018 Q3	$98K	Buy	1,670 +78	+5%	+$4.6K	﹤0.01%	3655
2018 Q2	$84K	Buy	1,592 +293	+23%	+$76.4K	﹤0.01%	3646
2018 Q1	$366K	Buy	1,299 +238	+22%	+$65.7K	﹤0.01%	3475
2017 Q4	$250K	Buy	1,061 +378	+55%	+$88.6K	﹤0.01%	3544
2017 Q3	$193K	Buy	683 +98	+17%	+$28.1K	﹤0.01%	3607
2017 Q2	$164K	Hold	585	–	–	﹤0.01%	3540
2017 Q1	$195K	Buy	585 +15	+3%	+$5.27K	﹤0.01%	3507
2016 Q4	$188K	Hold	570	–	–	﹤0.01%	3497
2016 Q3	$153K	Sell	570 -25	-4%	-$5.04K	﹤0.01%	3419
2016 Q2	$78K	Buy	+595	New	+$94.6K	﹤0.01%	3560

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

State Street's NGNE Position: Q1 2026 in Review

State Street increased its Neurogene (NGNE) stake by 1.7% in Q1 2026, buying an estimated $101K and bringing the position to 313,005 shares worth $6.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2842.

State Street first reported a position in NGNE in Q2 2016 and has held it in 39 quarters since. The position peaked at $19.4M in Q1 2021. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

State Street held 313,005 shares of Neurogene worth $6.31M as of Q1 2026.
State Street bought 5,208 Neurogene shares in Q1 2026, an estimated $101K.
Neurogene made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2842 holding.
State Street first reported a position in Neurogene in Q2 2016 and has held it in 39 quarters since.
State Street's Neurogene position peaked at $19.4M in Q1 2021.
96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.